Development and evaluation of novel LRRK2 inhibitors as PET ligands for in vivo imaging of LRRK2

Volume: 60, Pages: 1105 - 1105
Published: May 1, 2019
Abstract
1105 null Objectives: null null There is an urgent need for the development of Parkinson9s disease (PD) treatments that can slow disease progression. LRRK2 (leucine-rich repeat kinase 2) has recently been identified as a causative gene for autosomal dominant Parkinson’s disease (PD), with LRRK2 mutation G2019S linked to the most frequent familial form of PD. Several LRRK2 inhibitors have been developed and evaluated in vitro; however, in vivo...
Paper Details
Title
Development and evaluation of novel LRRK2 inhibitors as PET ligands for in vivo imaging of LRRK2
Published Date
May 1, 2019
Volume
60
Pages
1105 - 1105
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.